Earnings ·
Atara Biotherapeutics reported a net loss of $4.8 million for the quarter ended June 30, 2026, compared to net income…
ATRAAtara Biotherapeutics, Inc.
Atara Biotherapeutics reported a net loss of $4.8 million for the quarter ended June 30, 2026, compared to net income of $2.4 million in the prior year period. Cash and short-term investments totaled $9.9 million as of June 30, 2026, with a cash runway extending into mid-2027. The company held a productive Type A meeting with the FDA regarding tabelecleucel (EBVALLO), confirming the opportunity to resubmit the Biologics License Application based on the Phase 3 ALLELE trial data. Atara is eligible for a $31 million milestone payment upon FDA approval of the BLA under its agreement with Pierre Fabre Pharmaceuticals. The company operates in the biotechnology industry, developing allogeneic T-cell immunotherapies for cancer and autoimmune diseases.